The Disposition of Recainam Hydrochloride During and After Intravenous Loading and Maintenance Infusion in Cardiac Patients

Edward M. Hampton,M. Anastasiou-Nana,J. Nanas,J. Nappi,D. Capuzzi,Jeffrey L. Anderson
DOI: https://doi.org/10.1002/j.1552-4604.1987.tb05595.x
1987-12-01
Abstract:Recainam hydrochloride is a newly synthesized propylurea compound demonstrating potent antidysrhythmic effects. Recainam was administered as a loading dose of 3 mg/kg/40 minutes followed by a continuous infusion of 0.9 mg/kg/hr for 23 hours and 20 minutes to ten patients with cardiac disease and frequent PVCs (more than 30/hr). A total of 15 plasma samples were drawn over 36 hours during and after the infusion. Plasma recainam concentration was determined by high performance liquid chromatography (HPLC). The mean (± SD) postload and 24‐hour plasma concentrations were 5.19 ± 0.51 and 3.41 ± 0.71 μg/mL, respectively. The data were best described by a two‐compartment model yielding the following mean (± SD) pharmacokinetic parameters: λ1 = 2.62 ± 0.68 hr−1, λ2 = 0.144 ± 0.014 hr−1, t1/2 λ2 = 4.84 ± 0.46 hr, CLT = 0.268 ± 0.057 L/hr/kg, CLR = 0.143 ± 0.052 L/kg/hr, CLNR = 0.125 ± 0.041 L/hr/kg, Vdss =1.3 ± 0.19 L/kg, and Vdλ2 = 1.9 ± 0.43 L/kg. There were no adverse reactions. Based on these data, recainam can be safely administered as a loading dose followed by a continuous infusion in patients with stable cardiac disease without significant ventricular dysfunction.
What problem does this paper attempt to address?